RxDoctor Payments Data

Ronald Lewis, MD

Cardiovascular Disease · Newark, DENPI 1790751741

Payments from drug & device makers

$240in general payments, 2019–2025

Across 14 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$49
  • Amgen$23
  • Impulse Dynamics (USA) Inc.$22
  • Pfizer$21
  • Johnson & Johnson$19
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$240 in reported general payments places this provider in the 10th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$122,768
Medicare patients
1,238
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban369$545,812
XareltoRivaroxaban155$205,737
Repatha SureclickEvolocumab77$74,209
EntrestoSacubitril/Valsartan30$32,600
JardianceEmpagliflozin27$30,940
Praluent PenAlirocumab29$27,448
VascepaIcosapent Ethyl12$12,594
Rosuvastatin Calcium481$11,391
Clonidine43$9,698
Ezetimibe266$9,494
Atorvastatin Calcium589$7,846
Metoprolol Succinate498$7,147
Verapamil Er PmVerapamil Hcl11$4,557
Diltiazem 24hr Er (Cd)Diltiazem Hcl107$3,288
Icosapent Ethyl15$3,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$545,812369 claims
Johnson & JohnsonXarelto$19$205,737155 claims
NovartisEntresto$92$32,60030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →